ABSTRACT
We report a quite rare case of acquired type 3-like von Willebrand syndrome (vWS) that preceded full-blown systemic lupus erythematosus (SLE). A 16-year-old woman with no previous disease history and no family history of hemorrhagic diathesis was referred to our hospital because of recurrent epistaxis and gingival bleeding. She was diagnosed as having atypical type 3 von Willebrand disease because of prolonged bleeding time with normal platelet count and prolonged activated partial thromboplastin time (aPTT), and an almost complete absence of von Willebrand factor (vWF) antigen, ristocetin cofactor activity (vWF:RCo) and ristocetin-induced platelet agglutination (RIPA). Furthermore, electrophoretic analysis of plasma vWF revealed a trace amount of vWF and an absence of the multimeric form of vWF. Infusions of either vasopressin or factor VIII/vWF concentrates improved bleeding symptoms and corrected the aPTT and RIPA. However, she complained of low-grade fever, general fatigue and polyarthralgia 5 months later, and leukocytepenia and hypo-complementemia developed. Anti-double-stranded DNA antibodies and lupus erythematosus cells became positive. These findings were compatible with SLE. Mixing the patient's platelet-poor plasma (PPP) with normal platelet-rich plasma (PRP) (PPP/PRP = 2/1) resulted in a complete inhibition of RIPA, suggesting the presence of vWF inhibitor in her plasma. Treatment with prednisolone (40 mg/day) started and the bleeding tendency gradually improved. One month later, all of the laboratory data including aPTT, bleeding time, RIPA and vWF:RCo became normal. These findings indicate that she has an acquired type 3-like vWS associated with SLE.
Subject(s)
Lupus Erythematosus, Systemic/complications , von Willebrand Diseases/complications , Adolescent , Deamino Arginine Vasopressin/administration & dosage , Deamino Arginine Vasopressin/pharmacology , Female , Hemorrhage/drug therapy , Hemorrhage/etiology , Humans , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Prednisolone/administration & dosage , von Willebrand Diseases/diagnosis , von Willebrand Diseases/drug therapyABSTRACT
Recent clinical trials of gene therapy for patients with thoracic cancers have shown that these treatments were well tolerated with minimal side effects and that we need to further enhance specificity as well as efficiency of gene transfer to target cancer cells. We previously reported that myc-overexpressing SCLC cell lines became selectively sensitive to ganciclovir (GCV) by transducing the herpes simplex virus thymidine kinase (HSV-TK) gene under the control of the Myc-Max response elements (a core nucleotide sequence, CACGTG) and that this construct (MycTK) could be utilized to develop a novel treatment against chemo-radio-resistant SCLC. We report here in vivo antitumor effects and safety of a replication-deficient adenoviral vector containing the Myc-Max binding motif (AdMycTK) on SCLC cells. In vitro infection with AdMycTK selectively rendered myc-overexpressing SCLC cell lines 63- to 307-fold more sensitive to GCV. In vivo injections with AdMycTK followed by GCV administration markedly suppressed the growth of myc-overexpressing tumors established in the subcutis or in the peritoneal cavity of athymic mice. On the other hand, infection with AdMycTK did not significantly affect either in vitro GCV sensitivity of the cells expressing very low levels of the myc genes or the growth of their subcutaneous tumors. Moreover, we observed no apparent side effects of this treatment including body weight loss or biochemical abnormalities in contrast to the treatment with AdCATK that conferred strong but nonspecific expression of the HSV-TK gene. These results suggested that AdMycTK/GCV therapy is effective on SCLC patients whose tumors overexpress myc family oncogenes.
Subject(s)
Adenoviridae/genetics , Carcinoma, Small Cell/therapy , DNA-Binding Proteins/genetics , Genes, myc/genetics , Genetic Therapy/methods , Lung Neoplasms/therapy , Transcription Factors , Animals , Antiviral Agents/pharmacology , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Basic-Leucine Zipper Transcription Factors , Blotting, Northern , Carcinoma, Small Cell/enzymology , Carcinoma, Small Cell/genetics , Cell Division/drug effects , Cell Division/physiology , Ganciclovir/pharmacology , Gene Expression , Humans , Injections, Subcutaneous , Lac Operon , Liver Function Tests , Lung Neoplasms/enzymology , Lung Neoplasms/genetics , Mice , Mice, Inbred BALB C , Mice, Nude , Peritonitis/pathology , Promoter Regions, Genetic , Thymidine Kinase/biosynthesis , Thymidine Kinase/genetics , Transfection , Tumor Cells, CulturedABSTRACT
A case of malignant melanoma in the thymus is reported. Diagnostic imaging demonstrated a left anterior mediastinal mass in a patient with giant pigmented nevus without malignant change. Histologic and cytologic specimens obtained from the tumor revealed that the tumor was malignant melanoma. Surgery revealed malignant melanoma in the left lobe of the thymus. Many cell nests of pigmented nevi were observed throughout the thymus. The malignant melanoma was thought to have originated from the nevocellular nevus in the thymus. This is the first report of malignant melanoma in the thymus.
Subject(s)
Melanoma/pathology , Thymus Neoplasms/pathology , Adult , Female , Humans , Melanoma/etiology , Nevus, Pigmented/complications , Nevus, Pigmented/pathology , Thymus Neoplasms/etiologyABSTRACT
A considerable number of studies of cancer have shown that the cell type-specific promoter is an effective tool for selective expression of foreign genes in tumor cells. However, few reports have demonstrated significant in vivo antitumor effects using this strategy thus far, possibly because the low activity of such a promoter results in insufficient expression of genes in cancer cells as well as in insignificant antitumor effects, even when the cells are infected by highly efficient gene transfer methods. To overcome this problem, we used the Cre/loxP system for the cell type-specific gene therapy against carcinoembryonic antigen (CEA)-producing cancer. We constructed a pair of recombinant Ads. One expresses the Cre recombinase (Cre) gene under the control of the CEA promoter (Ad.CEA-Cre). The other contains the herpes simplex virus thymidine kinase (HSV-TK) gene separated from the strong CAG promoter by insertion of the neomycin resistance (neo) gene (Ad.lox-TK). The HSV-TK gene of the latter Ad is designed to be activated through excisional deletion of the neo gene by Cre enzyme released from the former one only when CEA-producing cells are infected simultaneously with these Ads. Coinfection by these Ads rendered a human CEA-producing cancer cell line 8.4-fold more sensitive to ganciclovir (GCV) compared with infection by Ad.CEA-TK alone, the HSV-TK gene of which is directly regulated by the CEA promoter. On the other hand, coinfection with these Ads did not significantly change the GCV sensitivity of non-CEA-producing cells. Intratumoral injection of Ad.CEA-Cre combined with Ad.lox-TK followed by GCV treatment almost completely eradicated CEA-producing tumors established in the subcutis of athymic mice, whereas intratumoral injection of Ad.CEA-TK with GCV administration at most retarded the growth of inoculated tumors. These results suggest distinct advantages of the Cre/loxP system applied in the conventional cell type-specific gene therapy against cancer.
Subject(s)
Adenocarcinoma/therapy , Carcinoembryonic Antigen/genetics , Colonic Neoplasms/therapy , Ganciclovir/therapeutic use , Genetic Therapy/methods , Integrases/genetics , Viral Proteins , Adenoviridae , Animals , Antiviral Agents/therapeutic use , Cell Line , Genetic Vectors , Humans , Integrases/metabolism , Male , Mice , Mice, Nude , Promoter Regions, Genetic , Simplexvirus/enzymology , Simplexvirus/genetics , Thymidine Kinase/genetics , Thymidine Kinase/metabolism , Transplantation, Heterologous , Tumor Cells, CulturedABSTRACT
Osteoclasts are derived from hematopoietic stem cells and their development is dependent on the products of stromal cells. CD9, a member of the tetraspan transmembrane-superfamily, is expressed on both hematopoietic cells and stromal cells. Addition of antagonistic rat anti-mouse CD9 antibody (KMC8.8) to cultures inhibited osteoclastogenesis on established stromal cell layers. When rat bone marrow cells depleted of adherent stromal cells were cultured on mouse stromal cells, numerous tartrate-resistant acid phosphatase-positive multinuclear cells were observed, and KMC8.8, which recognizes mouse but not rat CD9, completely prevented the generation of osteoclasts, suggesting that the CD9 expressed on the stromal cell is essential for osteoclastogenesis. Possibly for the same reason, KMC8.8 pretreatment of the mouse macrophage-like cell line C7, which is able to differentiate into mature osteoclasts, did not inhibit subsequent C7 cell differentiation, whereas the addition of KMC8.8 to cocultures of C7 cells with stromal cells inhibited the differentiation of C7 cells into osteoclasts. Moreover, we found that blockage of a signal via CD9 on stromal cells reduced transcription of the osteoclast differentiation factor (Odf) gene, which, together with macrophage colony-stimulating factor, is essential for osteoclastogenesis. These results revealed that CD9 molecules on stromal cells play a critical role in osteoclast development, possibly by modulating the expression of Odf.
Subject(s)
CD4 Antigens/immunology , Osteoclasts/cytology , Stromal Cells/immunology , Animals , Antibodies, Monoclonal/immunology , B-Lymphocytes/immunology , CD4 Antigens/analysis , Calcitriol/pharmacology , Carrier Proteins/genetics , Cell Division , Coculture Techniques , Dexamethasone/pharmacology , Gene Expression Regulation/immunology , Male , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Osteoclasts/immunology , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Stromal Cells/drug effectsABSTRACT
We report a rare case of primary malignant fibrous histiocytoma of the lung showing intracavitary fungus ball-like shadows. Fiberoptic bronchoscopy revealed no visible tumor, but adenocarcinoma cells were detected in samples of lavage fluid from the cavitary lesion. Staging procedures (T 2 N 0 M 0) confirmed that there were no metastatic lesions. A complete resection of the left lower lobe was performed. The tumor showed polypoid growth that obstructed a small peripheral bronchus, and formed a cavitary lesion. It was histologically diagnosed as an inflammatory type of malignant fibrous histiocytoma, and consisted of atypical histiocyte-like cells, neutrophils, lymphocytes, foamy cells, and fibroblast-like cells in a storiform pattern. The patient has been in complete remission for 3 years after surgery.
Subject(s)
Histiocytoma, Benign Fibrous/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Histiocytoma, Benign Fibrous/pathology , Humans , Inflammation , Lung Neoplasms/pathology , Male , Middle Aged , RadiographyABSTRACT
BACKGROUND: Serum angiotensin converting enzyme (SACE) is considered to reflect disease activity in sarcoidosis. SACE activity is increased in many patients with active sarcoid lesions. The mechanism for the increased SACE activity in this disease has not been clarified. ACE insertion/deletion (I/D) gene polymorphism has been reported to have an association with SACE levels in sarcoidosis, but no evidence of an association between angiotensin II receptor gene polymorphism and SACE in this disease has been found. A study of the association of angiotensin II receptor gene polymorphisms with sarcoidosis was therefore undertaken. METHODS: ACE (I/D), angiotensin II type 1 receptor (AGTR1), and angiotensin II type 2 receptor (AGTR2) gene polymorphisms were investigated by polymerase chain reaction (PCR) and SACE levels were measured in three groups of patients: those with sarcoidosis or tuberculosis and normal controls. RESULTS: There was no difference in allele frequency of AGTR1 and AGTR2 polymorphism among the three groups. Neither AGTR1 nor AGTR2 polymorphisms were associated with sarcoidosis. SACE activity was higher in patients with sarcoidosis with the AGTR1 A/C genotype than in others. However, this tendency was not detected in patients with tuberculosis. CONCLUSIONS: The AGTR1 allele C is associated with high activity of SACE in patients with sarcoidosis. It is another predisposing factor for high levels of SACE in patients with sarcoidosis and is considered to be an independent factor from the ACE D allele for high levels of SACE in sarcoidosis. This fact could be one of the explanations for the increased SACE activity in sarcoidosis.
Subject(s)
Angiotensin II , Lung Diseases/genetics , Peptidyl-Dipeptidase A/blood , Polymorphism, Genetic , Receptors, Angiotensin/genetics , Sarcoidosis/genetics , Analysis of Variance , Female , Genetic Techniques , Genotype , Humans , Lung Diseases/blood , Male , Middle Aged , Sarcoidosis/blood , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/geneticsABSTRACT
A case of ectopic thymoma of the pleura with a particular growth pattern mimicking diffuse pleural mesothelioma is reported. Diagnostic imaging showed that the pleural tumor encased the entire left lung. The specimen biopsied from the tumor was composed of lymphocytes and epithelial cells, consistent with the mixed type of thymoma. The autopsy found no evidence of a mediastinal tumor. An involuted thymus was found in the parietal pleural tissue adhered to the apex of the left lung. The thymoma was thought to originate from the ectopic thymic tissue in the parietal pleura, as a lesion independent from the primary mediastinal thymoma, and spread along the pleura like diffuse mesothelioma.
Subject(s)
Choristoma/pathology , Lung Neoplasms/pathology , Mesothelioma/pathology , Thymoma/pathology , Thymus Gland , Adult , Biopsy, Needle , Diagnosis, Differential , Fatal Outcome , Female , Humans , ImmunohistochemistryABSTRACT
Osteoclasts are hematopoietic cells which play important roles in bone remodeling and resorption. They have phenotypic characteristics of the monocyte/macrophage lineages. In this review we first describe the phylogeny of osteoclasts. Osteoclast generation is closely linked to the presence of bone tissues. The formation of bone cavities in aquatic animals is underdeveloped, even though they have cells which have the potential to differentiate into osteoclasts. Next we describe recent advances in our understanding of osteoclastogenesis that have resulted from the identification of critical molecules and mutated genes of osteopetrotic mice. Reports that transcriptional factors PU.1 and c-Fos are essential for commitment and (or) differentiation into the osteoclast lineage and novel culture systems, which have clarified some characteristics of osteoclast precursors, are also described. We are now able to induce mature osteoclasts from hematopoietic stem cells and even from totipotent embryonic stem cells. Cell lines that differentiate into osteoclasts are also available. Using these culture systems and cell lines, the interactions of osteoclasts with osteoblastic stromal cells, which produce critical molecules for osteoclastogenesis, have been studied. Very recently, one of these critical molecules, osteoclast differentiation factor/osteoprotegerin-ligand, was cloned. The presence of this factor and macrophage-colony-stimulating factor is sufficient to induce osteoclast development in cultures inoculated only with an osteoclast precursor cell line. We review the present status and the remaining questions in osteoclast biology.
Subject(s)
Cell Lineage , Hematopoietic Stem Cells/physiology , Osteoclasts/physiology , Animals , Bone Marrow Cells/physiology , Carrier Proteins/physiology , Cell Differentiation , Cells, Cultured , Humans , Macrophage Colony-Stimulating Factor/physiology , Membrane Glycoproteins/physiology , Mice , Mice, Mutant Strains , Models, Biological , Mutagenesis , Phylogeny , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Recombinant Proteins/pharmacologyABSTRACT
Whether chemotherapy or surgical resection is primarily selected for lung cancer therapy is determined based on the pathological diagnosis of small cell or non-small cell lung cancer. In future, however, each standard therapy should be established against the respective subgroups of lung cancer, which will be more precisely defined depending on the biological or the molecular basis, like malignant lymphoma. Much evidence is increasing to help understand the mechanisms mediating differences in clinical behavior and neuroendocrine features between small cell and non-small cell lung cancer. Here we showed the experimental models of tissue-specific gene therapy targeting CEA- or Myc-overexpressing lung cancer cell lines.
Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Small Cell/therapy , Genetic Therapy , Lung Neoplasms/therapy , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Animals , Carcinoembryonic Antigen/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/pathology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Genes, myc , Genetic Vectors , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Male , Mice , Mice, Nude , Middle Aged , Retroviridae/genetics , Thymidine Kinase/geneticsABSTRACT
IMR32, a neuroblastoma cell line, and CADO LC6, a small cell lung cancer (SCLC) cell line, extended neurite-like processes when cultured on fibronectin (FN)-coated surfaces or cultured in a serum-free medium. Monoclonal antibodies against the integrin beta 1 subunit inhibited this process formation, suggesting that their morphological change is initiated by beta 1 integrin-dependent signal transduction to the cell interior. Anti-phosphorylation level of a 100-kDa protein, but not 125-kDa focal adhesion kindase, correlated well with the morphological change in both cell lines. This 100-kDa protein phosphorylation did not accompany FN-induced morphological changes in NIH 3T3 fibroblasts or A549 adenocarcinoma cells. These findings suggest that neuroblastoma and SCLC may share beta 1 integrin-mediated signaling events distinct from nonneuronal cells.
Subject(s)
Carcinoma, Small Cell/pathology , Integrin beta1/pharmacology , Neuroblastoma/pathology , Signal Transduction/physiology , Tyrosine/metabolism , Adenocarcinoma , Benzoquinones , Blotting, Western , Cell Adhesion/physiology , Cell Adhesion Molecules/metabolism , Cell Differentiation/physiology , Enzyme Inhibitors/pharmacology , Flow Cytometry , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Lactams, Macrocyclic , Lung Neoplasms , Phosphorylation , Protein-Tyrosine Kinases/metabolism , Quinones/pharmacology , Receptor, Insulin/metabolism , Rifabutin/analogs & derivatives , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/enzymologyABSTRACT
Herpes simplex virus thymidine kinase (HSV-TK) gene was ligated with four repeats of the Myc-Max response elements (a core nucleotide sequence CACGTG), and its utility for gene therapy was examined by the treatment of either c-, L- or N-myc-overexpressing the small cell lung cancer (SCLC) cell line with ganciclovir (GCV). The chloramphenicol acetyltransferase assay demonstrated that the overexpression of any myc genes activated transcription from the CAT gene depending on the Myc-Max binding sites. The transduction of the HSV-TK gene ligated with the CACGTG core rendered all three SCLC lines to be more sensitive to GCV than parental ones in vitro. In addition, the growth of c- or L-myc-overexpressing SCLC cells containing the hybrid HSV-TK gene were significantly suppressed by GCV in vivo. When parental SCLC cells were mixed with HSV-TK-expressing tumor cells at a ratio of 1:3, GCV treatment inhibited tumor growth by 90% compared with parental cells only, indicating the existence of the "bystander effect." These data suggest that the CACGTG-driven HSV-TK gene may be useful for the treatment of SCLC overexpressing any type of myc family oncogenes.
Subject(s)
Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/therapy , Genes, myc , Genetic Therapy , Lung Neoplasms/genetics , Lung Neoplasms/therapy , Simplexvirus/enzymology , Thymidine Kinase/genetics , Antimetabolites, Antineoplastic/pharmacology , Base Sequence , Carcinoma, Small Cell/enzymology , Cell Division/drug effects , Cell Division/physiology , Ganciclovir/pharmacology , Gene Expression , Humans , Lung Neoplasms/enzymology , Molecular Sequence Data , Promoter Regions, Genetic , Simplexvirus/genetics , Thymidine Kinase/biosynthesis , Transfection , Tumor Cells, CulturedABSTRACT
A carcinoembryonic antigen (CEA)-producing human lung cancer cell line (A549), a nonproducing human lung cancer cell line (CADO-LC9), and a human uterine cervical cancer (HeLa) were transfected with the herpes simplex virus thymidine kinase (HSV-TK) gene regulated by 445 nucleotides upstream from the translational start of CEA gene. Fifty % growth inhibitory concentration of ganciclovir (GCV) was 0.57 micron for HSV-TK-transfected A549; relative sensitivity to GCV was more than 1000 times higher compared to the 50% growth inhibitory concentration of the parental cell line. Both CADO-LC9 and HeLa transfected with HSV-TK were still resistant to GCV. There was no difference in either morphology or doubling time between HSV-TK-transfected and parental clones. Injections (i.p.) of GCV resulted in significant regression of HSV-TK-transfected A549 tumors in nude mice. These data show the possibility of gene therapy using the cell type-specific promoter of CEA gene against CEA-producing adenocarcinoma of the lung.
Subject(s)
Adenocarcinoma/therapy , Biomarkers, Tumor/metabolism , Carcinoembryonic Antigen/metabolism , Carcinoma, Small Cell/therapy , Ganciclovir/pharmacology , Genes, Viral , Genetic Therapy/methods , Lung Neoplasms/therapy , Simplexvirus/genetics , Thymidine Kinase/genetics , Adenocarcinoma/metabolism , Base Sequence , Biomarkers, Tumor/genetics , Carcinoembryonic Antigen/genetics , Carcinoma, Small Cell/metabolism , Female , Gene Expression Regulation, Enzymologic , HeLa Cells/metabolism , Humans , Lung Neoplasms/metabolism , Molecular Sequence Data , Neoplasm Recurrence, Local/therapy , Promoter Regions, Genetic/genetics , RNA, Messenger/metabolism , Simplexvirus/enzymology , Transfection , Tumor Cells, Cultured , Uterine Neoplasms/metabolism , Uterine Neoplasms/therapyABSTRACT
A 47-year-old woman, with a history of recurrent venous thrombosis in her lower limbs (1988 and June, 1992), was admitted because of pulmonary thromboembolism in the right middle lung lobe. She was given anti-coagulant therapy with warfarin. The consolidation in the right middle lobe disappeared within two months. Hematological examinations concerning the coagulation and fibrinolytic system showed a significant decrease in both the serum concentration and the activity of protein C, a vitamin K-dependent hepatic protein which acts as an anticoagulant by shutting off fibrin formation and stimulating fibrinolysis. Since a sister of the patient also has a history of venous thrombosis, several members of her family were tested for protein C deficiency. The familial study revealed that her sister and mother had both a decreased concentration and depressed activity of protein C, indicating that this is a case of congenital protein C deficiency. Warfarin therapy has been continued to reduce the prothrombin time to 70% of the normal control level, resulting in no further episodes of thrombosis.
Subject(s)
Protein C Deficiency , Pulmonary Embolism/etiology , Thrombophlebitis/etiology , Female , Humans , Middle Aged , Protein C/genetics , Prothrombin Time , Pulmonary Embolism/drug therapy , Recurrence , Thrombophlebitis/drug therapy , Warfarin/administration & dosage , Warfarin/therapeutic useABSTRACT
We have examined the deletion of the long arm of chromosome 5 (5q) in 59 cases of advanced lung cancer [39 cases of small cell lung cancer (SCLC), 20 cases of non-SCLC] using 12 restriction fragment length polymorphism markers on 5q. Of 59 lung cancer cases, 48 (81%) exhibited deletion at any portion of the 5q locus (loci). Such a high frequency of 5q deletion has not been reported in surgically resectable non-SCLC. One SCLC case showed a 5q deletion only in metastatic sites but not in the primary cancer. These data suggest that the inactivation of putative tumor-suppressor gene(s) on 5q may be a late event in the progression of lung cancer. There was no significant difference in frequency of 5q deletion between SCLC and non-SCLC. Compared to non-SCLC, however, SCLC usually showed widespread deletion on 5q. While the most frequent target region was estimated to be about 3-5 megabases at 5q21 around the adenomatous polyposis coli (APC) gene locus, some cases showed more telomeric deletion (5q33-35), suggesting that there are at least two different tumor-suppressor genes on 5q associated with the progression of lung cancer.
Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Small Cell/genetics , Chromosome Deletion , Lung Neoplasms/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/pathology , Chromosome Mapping , DNA, Neoplasm/analysis , Electrophoresis, Agar Gel , Genes, APC , Genes, Tumor Suppressor , Genetic Markers , Lung Neoplasms/pathology , Polymorphism, Restriction Fragment LengthABSTRACT
The neural cell adhesion molecule (N-CAM), a member of the immunoglobulin gene super-family mediating homophilic cell-cell adhesion in a neuroendocrine system, is preferentially expressed in human small cell lung cancer (SCLC). Immunoprecipitation of a panel of SCLC cell lines by monoclonal antibodies (mAbs) specific for N-CAM detects mainly the 145-kDa isoform. This result was correlated with Northern blotting where a single 6.2-kb mRNA was detected in nine SCLC cell lines. To determine cDNA sequence encoding the N-CAM isoform, we selected several cDNA clones encoding N-CAM isolated from OS2-R, a SCLC cell line established in our laboratory. Based on the analysis of the full-length cDNA obtained from two clones, the sequence of this 145-kDa isoform was shown to be essentially identical to that of the 140-kDa N-CAM isoform of neuroblastoma except for a single base pair changed at position 1620 without changing amino acid encoded.
Subject(s)
Carcinoma, Small Cell/chemistry , Cell Adhesion Molecules, Neuronal/genetics , DNA, Complementary/chemistry , Lung Neoplasms/chemistry , Amino Acid Sequence , Base Sequence , Blotting, Northern , Cell Adhesion Molecules, Neuronal/chemistry , DNA, Complementary/isolation & purification , Humans , Molecular Sequence Data , Tumor Cells, CulturedABSTRACT
We constructed a detailed deletion map of the short arm of chromosome 3 (3p) for 55 lung cancer cases by using 17 restriction fragment length polymorphism (RFLP) probes. Initially, we examined 40 small cell lung cancer (SCLC) cases and found three regions of deletion at 3p25-26, 3p21.3 and 3p14-cen, suggesting the possibility of at least three different tumor-suppressor genes on 3p. In order to obtain more detailed deletion area, and to compare the pattern of 3p deletion, we also examined 15 non-small cell lung cancer (NSCLC) cases. Compared to NSCLC cases, most of SCLC cases have widespread deletion on 3p, suggesting multiple tumor-suppressor genes on 3p may be inactivated in this type of cancer. In 3p21.3 area, minimum overlapping area of deletion lays between two probes which are close to each other. These data will be useful to isolate the putative tumor-suppressor genes located on the chromosome 3p.
Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Small Cell/genetics , Chromosome Deletion , Chromosomes, Human, Pair 3 , Lung Neoplasms/genetics , Chromosome Mapping , Humans , Polymorphism, Restriction Fragment LengthABSTRACT
The 5-year survival of lung cancer patients is about 30% in Japan. One of the reasons for the poor prognosis seems to be drug resistance. It has been reported that certain types of oncogenes, such as ras, myc and fos, may play an important role in drug resistance. The myc protein forms a sequence-specific DNA-binding complex with Max and may act as a transcription factor; thus, it may be possible that myc family oncogenes are involved in DNA synthesis and repair processes mediating drug resistance. We report here that L-myc oncogene may be involved in the transition from drug-sensitive to drug-resistant phenotype of a certain small cell lung cancer cell line.
Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Small Cell/genetics , Genes, myc , Lung Neoplasms/genetics , Animals , Drug Resistance/genetics , Humans , Mice , Transcription Factors , Tumor Cells, CulturedABSTRACT
Three cell lines of small cell lung cancer (SCLC), which were established from specimens of untreated primary tumors biopsied by diagnostic bronchofiberscopy, were analyzed for immunological characteristics. These cell lines showed considerable heterogeneity in chemo-radiosensitivity, which was well correlated with clinical responses of the respective tumors, but their HLA-class I antigen expressions were equally depressed and they were susceptible to peripheral blood lymphocytes (PBL) and lymphokine-activated killer (LAK) cells, irrespective of their diverse chemo-radiosensitivity. Treatment of the cell lines with recombinant immune interferon (rIFN-gamma) increased their HLA-class I antigen expression and conversely depressed PBL sensitivity but not LAK sensitivity. This inverse relationship between HLA-class I expression and PBL susceptibility was also demonstrated using other pairs of autologous PBL and SCLC cell lines. rIFN-gamma changed neither HLA-class II antigen nor SCLC-specific antigen expression under the same experimental conditions. In vitro immunization of allogeneic peripheral blood lymphocytes with rIFN-gamma-treated SCLC cells induced allo-specific killer cells which lysed rIFN-gamma-treated more strongly than non-treated SCLC cells. These results suggest that reduced HLA-class I antigen expression of SCLC could protect the cancer from attack of killer T cells in spite of the higher sensitivity to PBL or LAK cells.